Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: Results of an Italian cohort study on 120 patients characterized by bleeding severity score

Haemophilia

Volumn 16, Issue 1, 2010, Pages 101-110

  Federici, A B ^a   Barillari, G ^b   Zanon, E ^c   Mazzucconi, M G ^d   Musso, R ^e   Targhetta, R ^f   Mannucci, P M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f Osp Regionale per le Microcitemie   (Italy)

Author keywords

Alphanate ; Bleeding; Fanhdi ; Ristocetin cofactor unit; Secondary long term prophylaxis; Surgery; Von Willebrand's disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; FANHDI; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ABDOMINAL SURGERY; ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; ENDOCRINE SURGERY; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENITAL BLEEDING; GYNECOLOGIC SURGERY; HEMARTHROSIS; HEMATOMA; HUMAN; INHERITANCE; ITALY; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA; METRORRHAGIA; ORTHOPEDIC SURGERY; POSTOPERATIVE HEMORRHAGE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; SCHOOL CHILD; SCORING SYSTEM; THORAX SURGERY; TREATMENT OUTCOME; URINARY TRACT HEMORRHAGE; VASCULAR SURGERY; VIRUS INACTIVATION; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD LOSS, SURGICAL; CHILD; COHORT STUDIES; DRUG COMBINATIONS; FACTOR VIII; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VIRUS INACTIVATION; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 73949148650     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02088.x     Document Type: Article

References (32)

1. Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med 2007, 39:346-58.
2. Sadler JE, Budde U, Eikenboom JC. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006, 4:2103-14.
3. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002, 8:607-21.
4. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004, 351:683-94.
5. Federici AB. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007). Haemophilia 2008, 14:5-14.
6. Federici AB, Mazurier C, Berntorp E. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004, 103:2032-8.
7. Federici AB. The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease. Expert Opin Drug Safety 2009, 8:1-8.
8. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 2005, 16:S17-21.
9. Committee for Medicinal Products For Human Use Guideline On The Clinical Investigation Of Human Plasma Derived Von Willebrand Factor Products (CPMP/BPWG/220/02). http://www.emea.europa.eu/pdfs/human/bpwg/022002en.pdf, November 2005 ()
10. Mannucci PM, Chediak J, Hanna W. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002, 99:450-6.
11. Rivard GE, Aledort L. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia 2008, 14:271-5.
12. FDA Center for Biological Evaluation and Research. http://www.fda.gov/cber/products/alphanate.htm, January 21 2007 ()
13. Bello IF, Yuste VJ, Molina MQ, Navarro FH. Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. Haemophilia 2007, 13:25-32.
14. Federici AB, Baudo F, Caracciolo C. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia 2002, 8:761-7.
15. Hernandez-Navarro F, Quintana M, Jimenez-Yuste V, Alvarez MT, Fernandez-Morata R. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi® a highly purified, doubly inactivated FVIII/VWF concentrate. Haemophilia 2008, 14:963-7.
16. Tosetto A, Rodeghiero F, Castaman G. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006, 4:766-73.
17. Federici AB, Bucciarelli P, Castaman G. Incidence and determinants of bleeding in von Willebrand disease: results of the first prospective multicenter study on 814 Italian patients. http://www.haematologica.org/cgi/reprint/92/supplement_3/1, ; 28, Abstract CO-058
18. Ristol P, Gensana M, Fernandez J, Massot M, Bhattacharya P, Jorquera JI. [Development and characterization of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)]. Sangre (Barc) 1996, 41:125-30.
19. Rivera J, Escolar G, Casamiquela R. von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions. Haematologica 1999, 84:5-11.
20. Kosten T, Blann AD, Briet E, Vandenbrouche JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995, 345:152-5.
21. Kraaijenhagen RA, in't Anker PS, Koopman MM. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000, 83:5-9.
22. Wells PS, Langlois NJ, Webster MA, Jaffey J, Anderson JA. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada - is it necessary to define a new upper reference range for factor VIII? Thromb Haemost 2005, 93:842-6.
23. Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood 2008, 111:3998-400.
24. Federici AB, Castaman G, Franchini M. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica 2007, 92:944-51.
25. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002, 87:224-230.
26. Franchini M, Rossetti G, Tagliaferri A. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003, 88:1279-83.
27. Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003, 9:688-95.
28. Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia 2004, 10:42-51.
29. Berntorp E, Baghaei F, Holmström M. Long-term prophylaxis in VWD. The Swedish experience. The International Society on Thrombosis & Haemostasis XXth Congress, Sydney 2005, Australia [Abstract 01444]
30. Federici AB. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO.WILL Study. Haemophilia 2007, 13:15-24.
31. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002, 88:378-9.
32. Summary of product characteristics of Fanhdi (Instituto Grifols, S.A.) and Alphanate (Alpha Therapeutic Italia S.p.A)